Back to results
US 2025/0145953 A1Published application
Use of histone modifiers to reprogram effector t cells
AssigneeBoard of Regents, The University of Texas System
InventorsCassian YEE, Junmei WANG
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for re-programming effector T cells to a central memory phenotype comprising culturing the effector T cells with a histone deacetylase inhibitor (HDACi) and IL-21. Further provided are methods of treating cancer comprising administering the central memory T cells.
Claims21
1-62. (canceled)
A method for reprogramming antigen-specific engineered T cells into central memory T cells (TCM cells), the method comprising:
- (a) obtaining a starting population of antigen specific engineered T cells;
- and
- (b) culturing the starting population of antigen specific engineered T cells in the presence of a histone deacetylase inhibitor (HDACi) and interleukin-21 (IL-21), each in an amount sufficient to re-program the engineered T cells into TCM cells, wherein the re-programming produces a population of lymphocytes enriched for TCM cells as compared to the number of TCM cells in the starting population of antigen specific engineered T cells.
Dependencies are inferred from the claim text.